The significant increase in CDK1, STAT1, COL1A2, and COL1A1 in the AKI group suggests that these genes may serve as early biomarkers for AKI and have clinical application potential in gastrointestinal cancer patients. Here, COL1A2 is linked to acute kidney injury.